Xin Yi
Research Subjects
Xin Yi has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Bingfa Yan
Geneplus-Beijing Institute, Beijing, China
17 shared publications - Chen Huang
Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
17 shared publications - Hai-Yan Tu
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
17 shared publications - Hong-Hong Yan
Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
17 shared publications - Jia-Tao Zhang
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China
17 shared publications - Qing Zhou
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
17 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S4. Clinical characteristics of 13 cases recurred with longitudinal undetected MRD.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S2. Kaplan-Meier Analysis of Disease-Free Survival (DFS) in the Overall Population.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S2. Kaplan-Meier Analysis of Disease-Free Survival (DFS) in the Overall Population.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Purpose:The prognostic value of molecular residual disease (MRD) in non–small cell lung cancer (NSCLC) is well established, with treatment-guiding results anticipated. Here, we present updated analyses from our previously published cohort study of 261 patients with NSCLC undergoing complete resection.Experimental Design:A total of 261 patients with stage I to III lung cancer who underwent radical surgery were enrolled. Enrolled patients underwent follow-up blood draws according to the predefined time points after surgery. As of December 31, 2023, with a median follow-up of 43.4 months, 948 postoperative blood samples were collected.Results:Landmark and longitudinal MRD exhibited positive predictive values of 91.3% and 92.8%, respectively, with a median lead time of 5.2 months. Negative predictive values were 76.5% and 93.2%, respectively. Patients with landmark undetectable MRD could not benefit from adjuvant therapy through the updated follow-up (P = 0.529). Among the 13 patients with recurrent NSCLC and longitudinal undetectable MRD, seven (53.8%) had brain-only metastases, and four (30.8%) had no updated blood samples for over 6 months prior to recurrence. Besides, for those with longitudinal detectable MRD, higher maximum variant allele frequency (>0.55%) and ctDNA level (>13 hGE/mL) were associated with a high risk of short-term recurrence. Additionally, updated follow-up data further support that the peak time for detectable MRD was 18 months after landmark detection.Conclusions:These findings suggest the significant potential of MRD in guiding personalized treatment for NSCLC. Postoperative longitudinal undetectable MRD can indicate a cured population.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Purpose:The prognostic value of molecular residual disease (MRD) in non–small cell lung cancer (NSCLC) is well established, with treatment-guiding results anticipated. Here, we present updated analyses from our previously published cohort study of 261 patients with NSCLC undergoing complete resection.Experimental Design:A total of 261 patients with stage I to III lung cancer who underwent radical surgery were enrolled. Enrolled patients underwent follow-up blood draws according to the predefined time points after surgery. As of December 31, 2023, with a median follow-up of 43.4 months, 948 postoperative blood samples were collected.Results:Landmark and longitudinal MRD exhibited positive predictive values of 91.3% and 92.8%, respectively, with a median lead time of 5.2 months. Negative predictive values were 76.5% and 93.2%, respectively. Patients with landmark undetectable MRD could not benefit from adjuvant therapy through the updated follow-up (P = 0.529). Among the 13 patients with recurrent NSCLC and longitudinal undetectable MRD, seven (53.8%) had brain-only metastases, and four (30.8%) had no updated blood samples for over 6 months prior to recurrence. Besides, for those with longitudinal detectable MRD, higher maximum variant allele frequency (>0.55%) and ctDNA level (>13 hGE/mL) were associated with a high risk of short-term recurrence. Additionally, updated follow-up data further support that the peak time for detectable MRD was 18 months after landmark detection.Conclusions:These findings suggest the significant potential of MRD in guiding personalized treatment for NSCLC. Postoperative longitudinal undetectable MRD can indicate a cured population.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S5. CT and MRI images of patients with brain-only metastases who had longitudinal undetectable MRD. The red arrows indicate the location of metastatic lesions.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S5. CT and MRI images of patients with brain-only metastases who had longitudinal undetectable MRD. The red arrows indicate the location of metastatic lesions.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S6. The circulating tumor DNA mutation results for 4 patients with lead time over 30 months.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S4. Kaplan-Meier analysis of the survival time since last blood, comparing patients with longitudinal undetectable MRD to those with longitudinal detectable MRD (last blood draw positive), excluding synchronous recurrences.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S4. Kaplan-Meier analysis of the survival time since last blood, comparing patients with longitudinal undetectable MRD to those with longitudinal detectable MRD (last blood draw positive), excluding synchronous recurrences.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S8. (A) Estimated hazard rate curves for event occurrences in stage II/III patients with landmark undetectable MRD, who received adjuvant therapy. (B) Estimated hazard rate curves for event occurrences in stage II/III patients with landmark undetectable MRD, who did not receive adjuvant therapy
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Supplementary Figure S8. (A) Estimated hazard rate curves for event occurrences in stage II/III patients with landmark undetectable MRD, who received adjuvant therapy. (B) Estimated hazard rate curves for event occurrences in stage II/III patients with landmark undetectable MRD, who did not receive adjuvant therapy
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S1. Performance Metrics of Landmark and Longitudinal MRD Analyses Stratified by Tumor Type.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S1. Performance Metrics of Landmark and Longitudinal MRD Analyses Stratified by Tumor Type.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S2. Cox regression for progression-free survival based on longitudinal MRD detection.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Table S2. Cox regression for progression-free survival based on longitudinal MRD detection.